Syngene International Q1 FY27: Revenue down 16% to Rs 736 cr

Weak start to FY27 as key client offtake drops

Syngene International reported a soft start to FY27, with the June 2026 quarter showing lower revenue and sharply weaker profitability. Consolidated revenue from operations fell 16% year-on-year to Rs 736 crore. Operating EBITDA dropped to Rs 91 crore and the operating EBITDA margin narrowed to 12%, compared with 24% in the year-ago quarter. The company linked the performance primarily to the absence of offtake from Zoetis, a major biologics manufacturing client, and an adverse foreign exchange hedge outcome during the quarter. It also cited attrition of a few clients in its research services business.

The quarter ended June 30, 2026, resulted in a consolidated net loss of Rs 9 crore, reversing a consolidated net profit of Rs 86.7 crore in Q1 FY26. The company also reported exceptional charges related to employee termination benefits during the quarter.

What management said drove the quarter

In its quarter commentary, management pointed to two operational issues that hit results at the same time. First was the loss of business from Zoetis, described as the absence of offtake during the quarter. This was also referenced as the lack of offtake from a major large molecule CDMO client.

Second was a foreign exchange hedge loss. Syngene disclosed a foreign exchange hedge loss of Rs 50 crore during Q1 FY27, which management said significantly impacted profitability. Another disclosure in the same set of updates referred to FX losses of Rs 48 crore (reported as Rs 480 million) alongside termination costs.

While revenue pressure lowered operating leverage, Syngene said part of the impact was offset by ongoing cost optimisation measures, including employee-related costs and other expenses.

Segment mix: Research services still the larger share

Syngene’s revenue mix remained led by research services. During Q1 FY27, research services accounted for 78% of sales, while CDMO contributed 22%. The segment split matters because the quarter’s revenue decline was linked to a large molecule CDMO offtake gap, even as research services also saw some client attrition.

The disclosed mix indicates that research services continues to be the core contributor to quarterly sales. But the quarter’s commentary shows that CDMO volumes can materially affect profitability when large clients pause or reduce offtake.

Profitability hit by hedging loss and lower utilisation

Operating EBITDA for Q1 FY27 was Rs 91 crore, with a 12% EBITDA margin. Management attributed the margin compression to lower revenues and the Rs 50 crore foreign exchange hedge loss. In the year-ago quarter, the EBITDA margin was reported at 24%.

Cost actions were visible in select expense lines. Material costs fell 20% year-on-year to Rs 173 crore, reflecting lower production volumes. Staff costs declined 3% year-on-year to Rs 281 crore, which the company linked to optimisation efforts.

Net loss, exceptional items, and differing profit bases

Syngene reported exceptional items linked to employee termination benefits during the quarter. One disclosure cited an exceptional charge of Rs 10 crore (net of tax) related to termination benefits, while another stated the company recognised an additional Rs 13.5 crore related to termination benefits in the June 2026 quarter.

On profitability, the quarter updates included multiple figures. One portion stated profit after tax before exceptional items was Rs 1 crore, and net loss was Rs 9 crore after an exceptional charge related to employee termination benefits. The quarterly highlights table also reported PAT before exceptional items at Rs 11 crore and PAT after exceptional items at a loss of Rs 9 crore.

Standalone and consolidated outcomes were also reported separately. On a standalone basis, Syngene reported revenue from operations of Rs 663 crore and a net loss of Rs 2.1 crore (reported as Rs 21 million). Consolidated revenue from operations was Rs 736 crore, with a consolidated net loss of Rs 9 crore (reported as Rs 90 million).

Key numbers for Q1 FY27

Guidance: single-digit revenue decline now expected

Management provided an updated FY27 outlook, signalling near-term pressure but expecting a better second half. The company said it expects degrowth in the first half of FY27, with business momentum improving in the second half.

For the full year, revenue is now projected to decline by a single digit in rupee terms. This was described as a downgrade from earlier expectations of roughly flat performance. Despite the Q1 margin compression, Syngene maintained guidance that EBITDA margins are expected to recover to the mid-20s range over FY27.

Corporate actions and operational developments

Syngene recommended a final dividend of Rs 1.25 per share, according to the quarter disclosures. The company also highlighted a US expansion move: Syngene USA Inc., its wholly-owned subsidiary, acquired a biologics manufacturing site in the United States from Emergent Manufacturing Operations Baltimore, LLC.

Separately, updates noted that newly appointed CEO Siddharth Mittal is initiating a commercial shift by doubling down on CDMO opportunities, as part of steps aimed at steering a recovery while keeping the mid-20% EBITDA margin guidance for the full year.

Investor events: board meeting and results call

Syngene said it would host its Q1 FY27 results conference call on Thursday, July 30, 2026 at 9:00 AM IST. The call followed a board meeting on Wednesday, July 29, 2026, where the company’s financial results for the quarter ended June 30, 2026 were to be considered and approved.

Why this quarter matters for investors

The Q1 FY27 print brings two issues into focus: customer concentration risk in CDMO and the earnings sensitivity to hedging outcomes. With revenue down 16% and the operating EBITDA margin at 12%, the quarter represents a sharp reset from the prior-year margin profile.

At the same time, management’s guidance implies that the company expects the revenue trend to remain weak in the first half of FY27, before improving later in the year. Investors are likely to track the pace of CDMO order inflows, the stability of research services accounts after noted client attrition, and whether margin recovery to the mid-20s range occurs as guided.

Conclusion

Syngene’s Q1 FY27 results reflected the combined impact of reduced Zoetis offtake, client attrition in research services, and a disclosed Rs 50 crore FX hedge loss, culminating in a consolidated net loss of Rs 9 crore. The company has guided for a single-digit full-year revenue decline in rupee terms, with EBITDA margins expected to recover to the mid-20s range. Near-term focus remains on execution through the first-half slowdown, and on updates from scheduled investor interactions following the July 2026 board meeting and results call.